Literature DB >> 17762886

Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development.

Jürgen Wess1, Richard M Eglen, Dinesh Gautam.   

Abstract

Muscarinic acetylcholine receptors (mAChRs), M(1)-M(5), regulate the activity of numerous fundamental central and peripheral functions. The lack of small-molecule ligands that can block or activate specific mAChR subtypes with high selectivity has remained a major obstacle in defining the roles of the individual receptor subtypes and in the development of novel muscarinic drugs. Recently, phenotypic analysis of mutant mouse strains deficient in each of the five mAChR subtypes has led to a wealth of new information regarding the physiological roles of the individual receptor subtypes. Importantly, these studies have identified specific mAChR-regulated pathways as potentially novel targets for the treatment of various important disorders including Alzheimer's disease, schizophrenia, pain, obesity and diabetes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17762886     DOI: 10.1038/nrd2379

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  220 in total

1.  M2 muscarinic acetylcholine receptors regulate long-term potentiation at hippocampal CA3 pyramidal cell synapses in an input-specific fashion.

Authors:  Fang Zheng; Jürgen Wess; Christian Alzheimer
Journal:  J Neurophysiol       Date:  2012-04-04       Impact factor: 2.714

2.  Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system.

Authors:  Evan P Lebois; Thomas M Bridges; L Michelle Lewis; Eric S Dawson; Alexander S Kane; Zixiu Xiang; Satyawan B Jadhav; Huiyong Yin; J Phillip Kennedy; Jens Meiler; Colleen M Niswender; Carrie K Jones; P Jeffrey Conn; C David Weaver; Craig W Lindsley
Journal:  ACS Chem Neurosci       Date:  2010       Impact factor: 4.418

Review 3.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

4.  AGAP1/AP-3-dependent endocytic recycling of M5 muscarinic receptors promotes dopamine release.

Authors:  Jacob Bendor; José E Lizardi-Ortiz; Robert I Westphalen; Markus Brandstetter; Hugh C Hemmings; David Sulzer; Marc Flajolet; Paul Greengard
Journal:  EMBO J       Date:  2010-07-27       Impact factor: 11.598

5.  The M3-muscarinic receptor regulates learning and memory in a receptor phosphorylation/arrestin-dependent manner.

Authors:  Benoit Poulin; Adrian Butcher; Phillip McWilliams; Julie-Myrtille Bourgognon; Robert Pawlak; Kok Choi Kong; Andrew Bottrill; Sharad Mistry; Jürgen Wess; Elizabeth M Rosethorne; Steven J Charlton; Andrew B Tobin
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-03       Impact factor: 11.205

6.  CaMKII hunkers down on the muscarinic M4 receptor to help curb cocaine-induced hyperlocomotion.

Authors:  Ivar S Stein; Johannes W Hell
Journal:  EMBO J       Date:  2010-06-16       Impact factor: 11.598

Review 7.  The antipsychotic potential of muscarinic allosteric modulation.

Authors:  Thomas M Bridges; Evan P LeBois; Corey R Hopkins; Michael R Wood; Carrie K Jones; P Jeffrey Conn; Craig W Lindsley
Journal:  Drug News Perspect       Date:  2010-05

Review 8.  Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders.

Authors:  Gregory J Digby; Jana K Shirey; P Jeffrey Conn
Journal:  Mol Biosyst       Date:  2010-06-25

Review 9.  Targeting glutamate synapses in schizophrenia.

Authors:  Julie R Field; Adam G Walker; P Jeffrey Conn
Journal:  Trends Mol Med       Date:  2011-09-28       Impact factor: 11.951

10.  N-Ethylmaleimide differentiates between the M2- and M4-autoreceptor-mediated inhibition of acetylcholine release in the mouse brain.

Authors:  Justine Etscheid; Klaus Mohr; Eberhard Schlicker
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-07-21       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.